Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, anti-catabolic and pro-anabolic properties on cartilage and synovial membrane. It has also recently been shown to have protective effects against subchondral bone remodelling. Following the end of the revision procedure by the Pharmacovigilance Risk Assessment Committee of the European Medicines Agency, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) constituted a panel of 11 experts to better define the real place of diacerein in the armamentarium for treating OA. Based on a literature review of clinical trials and meta-analyses, the ESCEO confirms that the efficacy of diacerein is similar to that of non-steroidal anti-inflammatory drugs (NSAIDs) after the first month of treatment, and superior to that of paracetamol. Additionally, diacerein has shown a prolonged effect on symptoms of several months once treatment was stopped. The use of diacerein is associated with common gastrointestinal disorders such as soft stools and diarrhoea, common mild skin reactions, and, uncommonly, hepatobiliary disorders. However, NSAIDs and paracetamol are known to cause potentially severe hepatic, gastrointestinal, renal, cutaneous and cardiovascular reactions. Therefore, the ESCEO concludes that the benefit-risk balance of diacerein remains positive in the symptomatic treatment of hip and knee osteoarthritis. Furthermore, similarly to other SYSADOAs, the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.

2nd Department of Medicine State Hospital Stockerau Centre for Rheumatology Lower Austria Karl Landsteiner Institute for Clinical Rheumatology Stockerau Austria

Department of Public Health Epidemiology and Health Economics University of Liège Liège Belgium

Division of Bone Diseases Geneva University Hospital and Faculty of Medicine Geneva Switzerland

Institute of Rheumatology and Clinic of Rheumatology Charles University Prague Czech Republic

MRC Lifecourse Epidemiology Unit and NIHR Nutrition Biomedical Research Centre University of Southampton Southampton UK

Osteoarthritis Research Unit University of Montreal Hospital Research Centre Notre Dame Hospital Montreal Canada

Rheumatology Department AP HP St Antoine Hospital Paris France

Rheumatology Service Hospital del Mar Universitat Autònoma de Barcelona Barcelona Spain

WHO Collaborating Centre for Metabolic Bone Diseases University of Sheffield Medical School Sheffield UK

Erratum v

Drugs Aging. 2017 May;34(5):413. doi: 10.1007/s40266-017-0457-7. PubMed

Zobrazit více v PubMed

Hunter DJ, Schofield D, Callander E. The individual and socioeconomic impact of osteoarthritis. Nat Rev Rheumatol. 2014;10(7):437–441. PubMed

Jordan KM, Arden NK, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) Ann Rheum Dis. 2003;62(12):1145–1155. doi: 10.1136/ard.2003.011742. PubMed DOI PMC

Jones AC, Doherty M. The treatment of osteoarthritis. Br J Clin Pharmacol. 1992;33(4):357–363. doi: 10.1111/j.1365-2125.1992.tb04052.x. PubMed DOI PMC

Pelletier JP, Martel-Pelletier J. Therapeutic targets in osteoarthritis: from today to tomorrow with new imaging technology. Ann Rheum Dis. 2003;62 (Suppl 2):ii79–ii82. PubMed PMC

McAlindon TE, Bannuru RR, Sullivan MC, Arden NK, Berenbaum F, Bierma-Zeinstra SM, et al. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthr Cartil. 2014;22:363–88 (Comment in: Osteoarthr Cartil. 2014;22(6):888–9; author’s reply 890–1; Corrigendum in: Osteoarthr Cartil. 2015;23(6):1026–34). PubMed

Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, et al. OARSI recommendations for the management of hip and knee osteoarthritis: part III: changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthr Cartil. 2010;18(4):476–499. doi: 10.1016/j.joca.2010.01.013. PubMed DOI

National Institute for Health and Clinical Excellence (NHS). Osteoarthritis: the care and management of osteoarthritis in adults. In: NICE clinical guideline 59. 2008. http://www.nice.org.uk/CG059. Accessed 1 Feb 2013.

Bruyere O, Cooper C, Pelletier JP, Branco J, Luisa Brandi M, Guillemin F, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: a report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) Semin Arthritis Rheum. 2014;44(3):253–263. doi: 10.1016/j.semarthrit.2014.05.014. PubMed DOI

Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010;2(2):95–104. doi: 10.1177/1759720X09359104. PubMed DOI PMC

Moldovan F, Pelletier JP, Jolicoeur FC, Cloutier JM, Martel-Pelletier J. Diacerhein and rhein reduce the ICE-induced IL-1 beta and IL-18 activation in human osteoarthritic cartilage. Osteoarthr Cartil. 2000;8:186–196. doi: 10.1053/joca.1999.0289. PubMed DOI

Martel-Pelletier J, Mineau F, Jolicoeur FC, Cloutier JM, Pelletier JP. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-alpha systems in human osteoarthritic synovium and chondrocytes. J Rheumatol. 1998;25(4):753–762. PubMed

Pelletier JP, Mineau F, Ranger P, Tardif G, Martel-Pelletier J. The increased synthesis of inducible nitric oxide inhibits IL-1ra synthesis by human articular chondrocytes: possible role in osteoarthritic cartilage degradation. Osteoarthr Cartil. 1996;4(1):77–84. doi: 10.1016/S1063-4584(96)80009-4. PubMed DOI

Yaron M, Shirazi I, Yaron I. Anti-interleukin-1 effects of diacerein and rhein in human osteoarthritic synovial tissue and cartilage cultures. Osteoarthr Cartil. 1999;7(3):272–280. doi: 10.1053/joca.1998.0201. PubMed DOI

Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336(15):1066–1071. doi: 10.1056/NEJM199704103361506. PubMed DOI

Martin G, Bogdanowicz P, Domagala F, Ficheux H, Pujol JP. Rhein inhibits interleukin-1beta-induced activation of MEK/ERK pathway and DNA binding of NF-kappaB and AP-1 in chondrocytes cultured in hypoxia: a potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation. 2003;27(4):233–246. doi: 10.1023/A:1025040631514. PubMed DOI

Ferreira Mendes A, Caramona MM, de Carvalho AP, Lopes MC. Diacerhein and rhein prevent interleukin-1 beta-induced nuclear factor-kappa B activation by inhibiting the degradation of inhibitor kappa B-alpha. Pharmacol Toxicol. 2002;91(1):22–8. PubMed

Mathieu P. L’interleukine 1: son role, son dosage, ses difficultés d’approche dans l’arthrose. Résultats d’une étude ‘pilote ‘ avec la diacerhéine (ART 50) dans la gonarthrose [Interleukin 1 its role, quantitative determination and the difficulties in studying its role in osteoarthritis. Results of a ‘pilot’ study with diacerein (ART 50) in knee osteoarthritis]. Rev Prat. 1999;49(Suppl 13):S15–8. French. PubMed

Felisaz N, Boumediene K, Ghayor C, Herrouin JF, Bogdanowicz P, Galerra P, et al. Stimulating effect of diacerein on TGF beta 1 and beta 2 expression in articular chondrocytes cultured with and without interleukin-1. Osteoarthr Cartil. 1999;7(3):255–264. doi: 10.1053/joca.1998.0199. PubMed DOI

Sanchez C, Mathy-Hartert M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE. Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol. 2003;65(3):377–388. doi: 10.1016/S0006-2952(02)01485-5. PubMed DOI

Schöngen RN, Giannetti BM, Van de Leur E, Reinards R, Greiling H. Effect of diacetylrhein on the phagocytosis of polymorphonuclear leucocytes and its influence on the biosynthesis of hyaluronate in synovial cells. Arzneimittelforschung. 1988;38(I)(5):744–8. PubMed

Pelletier JP, Lajeunesse D, Reboul P, Mineau F, Fernandes JC, Sabouret P, et al. Diacerein reduces the excess synthesis of bone remodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol. 2001;28(4):814–824. PubMed

Legendre F, Bogdanowicz P, Martin G, Domagala F, Leclercq S, Pujol JP, et al. Rhein, a diacerhein-derived metabolite, modulates the expression of matrix degrading enzymes and the cell proliferation of articular chondrocytes by inhibiting ERK and JNK-AP-1 dependent pathways. Clin Exp Rheumatol. 2007;25(4):546–555. PubMed

Pelletier JP, Mineau F, Fernandes JC, Duval N, Martel-Pelletier J. Diacerhein and rhein reduce the interleukin 1 beta stimulated inducible nitric oxide synthesis level and activity while stimulating cyclooxygenase-2 synthesis in human osteoarthritic chondrocytes. J Rheumatol. 1998;25(12):2417–2424. PubMed

Martel-Pelletier J, Mineau F, Caron J, Pelletier JP. Effect of diacerein/rhein on the Wnt system in human osteoarthritic subchondral bone [abstract]. Ann Rheum Dis. 2011;70(Suppl 3):354 (Abstract no. FRI0025).

Boileau C, Tat SK, Pelletier JP, Cheng S, Martel-Pelletier J. Diacerein inhibits the synthesis of resorptive enzymes and reduces osteoclastic differentiation/survival in osteoarthritic subchondral bone: a possible mechanism for a protective effect against subchondral bone remodelling. Arthritis Res Ther. 2008;10(3):R71. doi: 10.1186/ar2444. PubMed DOI PMC

Brandt KD, Smith G, Kang SY, Myers S, O’Connor B, Albrecht M. Effects of diacerhein in an accelerated canine model of osteoarthritis. Osteoarthr Cartil. 1997;5:438–449. doi: 10.1016/S1063-4584(97)80048-9. PubMed DOI

Smith GN, Jr, Myers SL, Brandt KD, Mickler EA, Albrecht ME. Diacerhein treatment reduces the severity of osteoarthritis in the canine cruciate-deficiency model of osteoarthritis. Arthritis Rheum. 1999;42(3):545–554. doi: 10.1002/1529-0131(199904)42:3<545::AID-ANR20>3.0.CO;2-4. PubMed DOI

Ghosh P, Xu A, Hwa SY, Burkhardt D, Little C. Evaluation des effets de la diacerhéine dans un modele ovin d’arthrose [Evaluation of the effects of diacerhein in an ovine model of osteoarthritis]. Rev Prat. 1998;48(Suppl 17):S24–30. French. PubMed

Bendele AM, Bendele RA, Hulman JF, Swann BP. Effets bénéfiques d’un traitement par la diacerhéine chez des cobayes atteints d’arthrose [The beneficial effects of diacerein treatment in a guinea pig model of osteoarthritis] Rev Prat. 1996;46:S35–S39. PubMed

Mazieres B, Berda L. Effect of diacerheine (ART 50) on an experimental post-contusive model of OA. Osteoarthr Cartil. 1993;1(1):47.

Kitadai HK, Takahashi HK, Straus AH, Ibanez JF, Lucas R, Kitadai FT, et al. Effect of oral diacerein (DAR) in an experimental hip chondrolysis model. J Orthop Res. 2006;24(6):1240–1248. doi: 10.1002/jor.20180. PubMed DOI

de Rezende MU, de Campos Gurgel HM, Vilaca Junior PR, Kuroba RK, Lopes AS, Phillipi RZ, et al. Diacerhein versus glucosamine in a rat model of osteoarthritis. Clinics. 2006;61(5):461–466. doi: 10.1590/S1807-59322006000500014. PubMed DOI

Marcolongo R, Fioravanti A, Adami S, Tozzi E, Mian M, Zampieri A. Efficacy and tolerability of Diacerhein in the treatment of osteoarthrosis. Curr Ther Res. 1988;43(5):878–887.

Nguyen M, Dougados M, Berdah L, Amor B. Diacerhein in the treatment of osteoarthritis of the hip. Arthritis Rheum. 1994;37(4):529–536. doi: 10.1002/art.1780370413. PubMed DOI

Delcambre B, Taccoen A. Etude d’ART 50 en pratique rhumatologique quotidienne [Study of ART 50 in daily rheumatological practice]. Rev Prat. 1996;46(6 Spec No):S49–S52. French. PubMed

Fagnani F, Bouvenot G, Valat JP, Bardin T, Berdah L, Lafuma A, et al. Medico-economic analysis of diacerein with or without standard therapy in the treatment of osteoarthritis. Pharmacoeconomics. 1998;13(1 Pt 2):135–146. doi: 10.2165/00019053-199813010-00013. PubMed DOI

Lequesne M, Berdah L, Gérentes I. Efficacité et tolérance de la diacerhéine dans le traitement de la gonarthrose et de la coxarthrose [Efficacy and tolerance of diacerhein in the treatment of gonarthrosis and coxarthrosis]. Rev Prat. 1998;48(Suppl 17):S31–5. French. PubMed

Chantre P, Cappelaere A, Leblan D, Guedon D, Vandermander J, Fournie B. Efficacy and tolerance of Harpagophytum procumbens versus diacerhein in treatment of osteoarthritis. Phytomedicine. 2000;7(3):177–183. doi: 10.1016/S0944-7113(00)80001-X. PubMed DOI

Pelletier JP, Yaron M, Haraoui B, Cohen P, Nahir MA, Choquette D, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000;43(10):2339–2348. doi: 10.1002/1529-0131(200010)43:10<2339::AID-ANR23>3.0.CO;2-P. PubMed DOI

Dougados M, Nguyen M, Berdah L, Mazieres B, Vignon E, Lequesne M. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Arthritis Rheum. 2001;44(11):2539–2547. doi: 10.1002/1529-0131(200111)44:11<2539::AID-ART434>3.0.CO;2-T. PubMed DOI

Pham T, Le Henanff A, Ravaud P, Dieppe P, Paolozzi L, Dougados M. Evaluation of the symptomatic and structural efficacy of a new hyaluronic acid compound, NRD101, in comparison with diacerein and placebo in a 1 year randomised controlled study in symptomatic knee osteoarthritis. Ann Rheum Dis. 2004;63(12):1611–1617. doi: 10.1136/ard.2003.019703. PubMed DOI PMC

Jayaram S, Shetty N, Krishnamurthy V, Sharma VD, Naik MN, Apsangikar PD. Clinical study of the efficacy and tolerability of diacerein in the treatment of mild to moderate osteoarthritis: a randomized, multicentre, comparative study. Indian Pract. 2005;58(11):683–691.

Zheng WJ, Tang FL, Li J, Zhang FC, Li ZG, Su Y, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a randomized, multicenter, double-dummy, diclofenac-controlled trial in China. APLAR J Rheumatol. 2006;9(1):64–69. doi: 10.1111/j.1479-8077.2006.00167.x. DOI

Pavelka K, Trc T, Karpas K, Vitek P, Sedlackova M, Vlasakova V, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007;56(12):4055–4064. doi: 10.1002/art.23056. PubMed DOI

Louthrenoo W, Nilganuwong S, Aksaranugraha S, Asavatanabodee P, Saengnipanthkul S, The Thai Study Group The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study. Osteoarthr Cartil. 2007;15(6):605–614. doi: 10.1016/j.joca.2007.02.021. PubMed DOI

Sharma A, Rathod R, Baliga VP. An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteo-arthritis of the knee (DOK). J Indian Med Assoc. 2008;106(1):54–6, 58. PubMed

Brahmachari B, Chatterjee S, Ghosh A. Efficacy and safety of diacerein in early knee osteoarthritis: a randomized placebo-controlled trial. Clin Rheumatol. 2009;28(10):1193–1198. doi: 10.1007/s10067-009-1225-9. PubMed DOI

Singh K, Sharma R, Rai J. Diacerein as adjuvant to diclofenac sodium in osteoarthritis knee. Int J Rheum Dis. 2012;15(1):69–77. doi: 10.1111/j.1756-185X.2011.01648.x. PubMed DOI

Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006;166(17):1899–906 (Erratum in: Arch Intern Med. 2007;167(5):444). PubMed

Fidelix TS, Soares B, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006;1:CD005117. PubMed PMC

Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014;2:CD005117. PubMed PMC

Bartels EM, Bliddal H, Schondorff PK, Altman RD, Zhang W, Christensen R. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthr Cartil. 2010;18(3):289–296. doi: 10.1016/j.joca.2009.10.006. PubMed DOI

Mattara L. DAR: indagini “controllate” nel trattamento della osteoartosi [DAR “Controlled” studies in treatment of osteoarthrosis]. Paper presented at: Simposio Proter sulla diacereina. 86th Congresso Nazionale della Societa Italiana di Medicina Interna, 1985 Sep 24–27; Sorrento, Italy. Italian.

Pietrogrande V, Leonardi M, Pacchioni C. Risultati della sperimentazione clinica in pazienti artrosici di un nuovo farmaco: la diacereina [Results of a clinical study with a new drug (Diacerein) in osteoarthritis patients]. Paper presented at: Simposio Proter sulla diacereina. 86th Congresso Nazionale della Societa Italiana di Medicina Interna, 1985 Sep 24–27; Sorrento, Italy. Italian.

Fioravanti A, Marcolongo R. Efficacia terapeutica della Diacereina (DAR) nell’artrosi del ginocchio e dell’ anca [Therapeutic effectiveness of Diacerhein (DAR) in arthrosis of knee and hip]. Paper presented at: Toscana Medicina Symposium on Diacereina, Pisa, Italy. 1985 Oct 1. Italian.

Mordini M, Nencioni C, Lavagni A, Camarri E. Diacereina VS naproxene nella coxo-gonoartrosi: studio randomizzato in doppio ciego [Diacerhein versus naproxen in coxo-gonarthrosis: double-blind randomized study]. Paper presented at: 27th Congresso Nazionale della Societa Italiana di Reumatologia, 1986 Oct 30–Nov 2; Montecatini, Italy. Italian.

Mantia S. A controlled study of the efficacy and tolerability of Diacetylrhein in the functional manifestations of osteoarthritis of the hip and the knee. A double-blind study versus diclofenac [study report]. Palermo (Italy): Hospital of Palermo; 1987.

Portioli I. A naproxen-controlled study on the efficacy and tolerability of diacetylrhein in the functional manifestations of osteoarthritis of the knee and hip. A double-blind study versus naproxen [study report]. Reggio Emilia (Italy): Hospital Santa Maria Nuova; 1987.

Tang FL, Wu DH, Lu ZG, Huang F, Zhou YX. The efficacy and safety of diacerein in the treatment of painful knee osteoarthritis. Paper presented at: 11th Asia Pacific League of Associations for Rheumatology (APLAR) Congress, International Convention Center (ICC), 2004 Sep 11–15; Jeju, Korea.

Ascherl R. Longterm treatment of osteoarthritis of the knee: a six months placebo-controlled clinical trial with diacerhein. Paper presented at: 2nd OARSI International Congress Symposium: Diacerhein and Interleukin 1 inhibition: a new therapeutical approach in osteoarthritis, 1995 Feb 4–5; Nice, France.

Schulitz KP. Clinical investigation of the efficacy and tolerance of Diacetylrhein (DAR) in the treatment of osteoarthritis of the knee [study report]. Cologne (Germany): Madaus AG; 1994 Oct 27. 468 p. Report No. R-DA139.

Combe B, Dougados M, Goupille P, Cantagrel A, Eliaou JF, Sibilia J, et al. Prognostic factors for radiographic damage in early rheumatoid arthritis: a multiparameter prospective study. Arthritis Rheum. 2001;44(8):1736–1743. doi: 10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO;2-I. PubMed DOI

EMA. European Medicines Agency, Assessment report for diacerein containing medicinal products. 2014 Aug 28. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diacerein/European_Commission_final_decision/WC500173145.pdf. Accessed 2 Jun 2015.

Renan X, Lepage M, Connan D, Carlhant D, Riche C, Verger P, et al. Cas clinique d’une hépatite fatale a la diacerhéine [Case report of fatal hepatitis from diacerein]. Thérapie. 2001;56(2):190–1. French (Comment in: Thérapie. 2001;56:637–638). PubMed

Mattei E, Marzoli GA, Oberto G, Brunetti MM. Diacerein effects on the cardiovascular function of the conscious dog following repeated oral administration [study report]. Rome (Italy): RTC Research Toxicology Centre; 2009. 81 p. RTC Study No. 70600.

Middel B, van Sonderen E. Statistical significant change versus relevant or important change in (quasi) experimental design: some conceptual and methodological problems in estimating magnitude of intervention-related change in health services research. Int J Integr Care. 2002;2:e15. doi: 10.5334/ijic.65. PubMed DOI PMC

Zhang W, Robertson J, Jones AC, Dieppe PA, Doherty M. The placebo effect and its determinants in osteoarthritis: meta-analysis of randomised controlled trials. Ann Rheum Dis. 2008;67(12):1716–23 (Comment in: Minerva. 2009;8(9):117). PubMed

Ratnaike RN, Jones TE. Mechanisms of drug-induced diarrhoea in the elderly. Drugs Aging. 1998;13(3):245–253. doi: 10.2165/00002512-199813030-00007. PubMed DOI

Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42(6):1364–1372. doi: 10.1002/hep.20948. PubMed DOI

Bessone F. Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage? World J Gastroenterol. 2010;16(45):5651–5661. doi: 10.3748/wjg.v16.i45.5651. PubMed DOI PMC

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jove J, et al. Transplantation for acute liver failure in patients exposed to NSAIDs or paracetamol (acetaminophen): the multinational case-population SALT study. Drug Saf. 2013;36(2):135–144. doi: 10.1007/s40264-012-0013-7. PubMed DOI PMC

Rahme E, Barkun A, Nedjar H, Gaugris S, Watson D. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada. Am J Gastroenterol. 2008;103(4):872–882. doi: 10.1111/j.1572-0241.2008.01811.x. PubMed DOI

Coxib and traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–79 (Comment in: Lancet. 2013; 382(9894): 746–748). PubMed PMC

Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med. 1999;106(5B):13S–24S. doi: 10.1016/S0002-9343(99)00113-8. PubMed DOI

Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM. Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: A population-based, nested case-control analysis. Am J Epidemiol. 2006;164(9):881–889. doi: 10.1093/aje/kwj331. PubMed DOI

Pazhayattil GS, Shirali AC. Drug-induced impairment of renal function. Int J Nephrol Renovasc Dis. 2014;7:457–468. PubMed PMC

Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis. 2015. PubMed PMC

Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2000;53:357–379. PubMed

Food and Drug Administration (US). FDA issues public health advisory on Vioxx as its manufacturer voluntarily withdraws the product. 2004. http://www.fda.gov/bbs/topics/news/2004/NEW01122.html. Accessed 9 Jul 2005.

Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–2029. doi: 10.1016/S0140-6736(04)17514-4. PubMed DOI

Chan AT, Manson JE, Albert CM, Chae CU, Rexrode KM, Curhan GC, et al. Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation. 2006;113(12):1578–1587. doi: 10.1161/CIRCULATIONAHA.105.595793. PubMed DOI

McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):1–18. doi: 10.1371/journal.pmed.1001098. PubMed DOI PMC

Walker AM. Quantitative studies of the risk of serious hepatic injury in persons using nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1997;40(2):201–208. doi: 10.1002/art.1780400204. PubMed DOI

Kowalski ML, Makowska JS, Blanca M, Bavbek S, Bochenek G, Bousquet J, et al. Hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs)—classification, diagnosis and management: review of the EAACI/ENDA and GA2LEN/HANNA. Allergy. 2011;66(7):818–829. doi: 10.1111/j.1398-9995.2011.02557.x. PubMed DOI

Sanmarkan AD, Sori T, Thappa DM, Jaisankar TJ. Retrospective analysis of Stevens–Johnson syndrome and toxic epidermal necrolysis over a period of 10 years. Indian J Dermatol. 2011;56(1):25–29. doi: 10.4103/0019-5154.77546. PubMed DOI PMC

Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med. 2000;160(6):777–784. doi: 10.1001/archinte.160.6.777. PubMed DOI

Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ. 2006;332(7553):1302–1308. doi: 10.1136/bmj.332.7553.1302. PubMed DOI PMC

Panova E, Jones G. Benefit-risk assessment of diacerein in the treatment of osteoarthritis. Drug Saf. 2015;38:245–252. doi: 10.1007/s40264-015-0266-z. PubMed DOI

Bruyere O, Cooper C, Arden N, Branco J, Brandi ML, Herrero-Beaumont G, et al. Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis. Drugs Aging. 2015;32(3):179–187. doi: 10.1007/s40266-015-0243-3. PubMed DOI PMC

Susceptibility of Staphylococcus aureus to Anti-Inflammatory Drugs with a Focus on the Combinatory Effect of Celecoxib with Oxacillin In Vitro

An international, multicentre, double-blind, randomized study (DISSCO): effect of diacerein vs celecoxib on symptoms in knee osteoarthritis